Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.36 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 2/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.31 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26294765 | 0.83 | CHRNB2 (0.38) | HDAC2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL12206738 | 0.79 | CHRNB2 (0.38) | HDAC2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10139547 | 0.79 | CHRNB2 (0.50) | HDAC2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21149672 | 0.78 | GAA (0.43) | TSHR | |
| SCHEMBL30674446 | 0.78 | CHRNB2 (0.47) | HDAC2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL21149326 | 0.77 | RORC (0.37) | HDAC2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL10190233 | 0.77 | NR1H2 (0.50) | RORC | |
| SCHEMBL14752960 | 0.76 | MAPT (0.39) | HDAC2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19686575 | 0.76 | CHRNB2 (0.40) | HDAC2CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL19686595 | 0.76 | CHRNB2 (0.37) | HDAC2CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | GILEAD SCIENCES, INC. (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10774053-B2 | HIV protease inhibitors | PRSS1, SERPINB1, FURIN | HDAC2 403/4885CHRNB2 4884/4885CHRNA4 4870/4885 |
| US-20190210978-A1 | HIV PROTEASE INHIBITORS | PRSS1, SERPINB1, HPN | HDAC2 315/4885CHRNB2 4883/4885CHRNA4 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.